MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism

Cancer Research

Volumn 74, Issue 20, 2014, Pages 5903-5913

  Akita, Hirofumi ^a   Marquardt, Jens U ^a,b   Durkin, Marian E ^a   Kitade, Mitsuteru ^a   Seo, Daekwan ^a   Conner, Elizabeth A ^a   Andersen, Jesper B ^a,c   Factor, Valentina M ^a   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; HEPATOCELLULAR CARCINOMA CELL LINE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ONCOGENE C MYC; SIDE POPULATION CELL; TUMOR GROWTH; TUMOR SPHEROID; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; CARCINOGENESIS; HEPG2 CELL LINE; HUMAN; LIVER TUMOR; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; SCID MOUSE; TUMOR VOLUME;

ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908133376     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0527     Document Type: Article

References (41)

1. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355:1253-61.
2. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010;120:3326-39.
3. Marquardt JU, Raggi C, Andersen JB, Seo D, Avital I, Geller D, et al. Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology 2011;54:1031-42.
4. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008;22:2755-66.
5. Cairo S, Wang Y, de Reynies A, Duroure K, Dahan J, Redon MJ, et al. Stem cell -like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci U S A 2010;107:20471-6.
6. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11.
7. Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S, et al. AKT (vakt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. Hepatology 2012;55:833-45.
8. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al. Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb Symp Quant Biol 2008;73:427-37.
9. Smith KN, Lim JM, Wells L, Dalton S. Myc orchestrates a regulatory network required for the establishment and maintenance of pluripotency. Cell Cycle 2011;10:592-7.
10. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76.
11. Murakami H, Sanderson ND, Nagy P, Marino PA, Merlino G, Thorgeirsson SS. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of cmyc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 1993;53:1719-23.
12. Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 1989;4:715-24.
13. Wu Y, Renard CA, Apiou F, Huerre M, Tiollais P, Dutrillaux B, et al. Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors. Oncogene 2002;21:1518-26.
14. Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 2009;69:2775-82.
15. Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 2008;135:1322-32.
16. Woo HG, Park ES, Lee JS, Lee YH, Ishikawa T, Kim YJ, et al. Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res 2009;69:4059-66.
17. Holczbauer A, Factor VM, Andersen JB, Marquardt JU, Kleiner DE, Raggi C, et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology 2013;145:221-31.
18. Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, et al. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res 2008;68:5132-42.
19. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al.MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-7.
20. Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer 2010;102:1636-44.
21. Walter D, Satheesha S, Albrecht P, Bornhauser BC, D'Alessandro V, Oesch SM, et al. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS ONE 2011;6:e19506.
22. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010;143:313-24.
23. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008;2:333-44.
24. Salmon P, Trono D. Production and titration of lentiviral vectors. Curr Protoc Hum Genet 2007;Chapter 12:Unit 12 0.
25. Pluta K, Luce MJ, Bao L, Agha-Mohammadi S, Reiser J. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J Gene Med 2005;7:803-17.
26. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004;24:8541-55.
27. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008;134:62-73.
28. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
29. Po A, Ferretti E, Miele E, De Smaele E, Paganelli A, Canettieri G, et al. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J 2010;29:2646-58.
30. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008;14:447-57.
31. Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 1994;265:2091-3.
32. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009;460:1132-5.
33. Thorgeirsson SS. The almighty MYC: orchestrating the micro-RNA universe to generate aggressive liver cancer. J Hepatol 2011;55:486-7.
34. Thorgeirsson SS, Factor VF. c-MYC network and cancer. Signaling pathways in liver diseases 2010; 2nd ed; Heidelberg, Berlin: Springer-Verlag 2010:359-65.
35. Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 2010;53:568-77.
36. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005;7:165-71.
37. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, et al. The tumor suppressor p53 regulates polarity of selfrenewing divisions in mammary stem cells. Cell 2009;138:1083-95.
38. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009;460:1140-4.
39. Beer S, Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh H, et al. Low-level shRNA cytotoxicity can contribute to MYCinduced hepatocellular carcinoma in adult mice. Mol Ther 2010;18:161-70.
40. Motohara T, Masuko S, Ishimoto T, Yae T, Onishi N, Muraguchi T, et al. Transient depletion of p53 followed by transduction of c-Myc and KRas converts ovarian stem-like cells into tumor-initiating cells. Carcinogenesis 2011;32:1597-606.
41. Aparicio S, Eaves CJ. p53: a new kingpin in the stem cell arena. Cell 2009;138:1060-2.